Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc.

NASDAQ:ALGS

Overview | Financials
Company Name Aligos Therapeutics, Inc.
Symbol ALGS
Currency USD
Price 39.34
Market Cap 136,281,628
Dividend Yield 0%
52-week-range 6.76 - 42.947
Industry Biotechnology
Sector Healthcare
CEO Dr. Lawrence M. Blatt MBA, Ph.D.
Website https://www.aligos.com

An error occurred while fetching data.

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184,

Related Stocks

Reneo Pharmaceuticals, Inc. logo

Reneo Pharmaceuticals, Inc.

RPHM

18.2 USD

Vaccinex, Inc. logo

Vaccinex, Inc.

VCNX

1.18 USD

Sensei Biotherapeutics, Inc. logo

Sensei Biotherapeutics, Inc.

SNSE

0.454 USD

Daxor Corporation logo

Daxor Corporation

DXR

7.95 USD

Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc.

CRDF

3.92 USD

Financials

Numbers are in millions USD

Numbers are in millions USD